However, this therapeutic strategy does not fully respond to other types of solid tumors, such as pancreatic and breast cancer due to insufficient mutation that hinders the recognition of neo-antigens or tumor cell surface expressing antigenic peptide molecules by CD8+ T cells [135]. Here, CD8A is linked to breast carcinoma.